IL165932A0 - Osteopontin oligodendrocytes and myelination - Google Patents

Osteopontin oligodendrocytes and myelination

Info

Publication number
IL165932A0
IL165932A0 IL16593204A IL16593204A IL165932A0 IL 165932 A0 IL165932 A0 IL 165932A0 IL 16593204 A IL16593204 A IL 16593204A IL 16593204 A IL16593204 A IL 16593204A IL 165932 A0 IL165932 A0 IL 165932A0
Authority
IL
Israel
Prior art keywords
myelination
osteopontin
oligodendrocytes
osteopontin oligodendrocytes
Prior art date
Application number
IL16593204A
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0224017.4A external-priority patent/GB0224017D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of IL165932A0 publication Critical patent/IL165932A0/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0622Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073Stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/585Integrins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/51Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/285Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Developmental Biology & Embryology (AREA)
IL16593204A 2002-06-25 2004-12-22 Osteopontin oligodendrocytes and myelination IL165932A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39103502P 2002-06-25 2002-06-25
GBGB0224017.4A GB0224017D0 (en) 2002-06-25 2002-10-16 Osteopontin oligodendrocytes and myelination
PCT/US2003/019864 WO2004001014A2 (en) 2002-06-25 2003-06-24 Osteopontin, oligodendrocytes and myelination

Publications (1)

Publication Number Publication Date
IL165932A0 true IL165932A0 (en) 2006-01-15

Family

ID=30001991

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16593204A IL165932A0 (en) 2002-06-25 2004-12-22 Osteopontin oligodendrocytes and myelination

Country Status (11)

Country Link
EP (1) EP1517695A4 (en)
JP (1) JP2005535313A (en)
CN (1) CN1662249A (en)
AU (1) AU2003278205B2 (en)
BR (1) BR0312042A (en)
CA (1) CA2489905A1 (en)
IL (1) IL165932A0 (en)
MX (1) MXPA04012803A (en)
NO (1) NO20045560L (en)
RU (1) RU2005101633A (en)
WO (1) WO2004001014A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005238092B2 (en) * 2004-05-03 2010-06-17 Peter Maccallum Cancer Institute Methods for stem cell expansion and differentiation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773350B2 (en) * 1999-04-15 2004-05-20 Children's Medical Center Corporation Methods and compositions for modulating an immune response
UA85368C2 (en) * 2001-05-17 2009-01-26 Эплайд Рисьорч Системз Ерс Холдинг Н.В. Use of osteopontin for the treatment and/or prevention of neurologic diseases
WO2003046135A2 (en) * 2001-11-21 2003-06-05 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods

Also Published As

Publication number Publication date
AU2003278205B2 (en) 2008-01-24
AU2003278205A1 (en) 2004-01-06
BR0312042A (en) 2005-05-24
EP1517695A4 (en) 2010-09-01
CN1662249A (en) 2005-08-31
JP2005535313A (en) 2005-11-24
EP1517695A2 (en) 2005-03-30
NO20045560L (en) 2004-12-20
WO2004001014A3 (en) 2004-12-29
WO2004001014A2 (en) 2003-12-31
MXPA04012803A (en) 2005-06-08
RU2005101633A (en) 2005-06-10
CA2489905A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
EP1539941A4 (en) Adzymes and uses thereof
AU2003279814A8 (en) Fluid-handling apparatus and methods
EP1575495A4 (en) Compounds and methods
EP1501544A4 (en) Alcam and alcam modulators
EP1467916A4 (en) Container and methods associated therewith
AU2003216221A1 (en) Attachment and articles using same
GB2395952B (en) Block copolymer and use thereof
IL165112A0 (en) Variant integrinpolypeptides and thereof
AU2003231827A8 (en) Pseudo-tissues and uses thereof
AU2003228355A8 (en) Adipocytes and uses thereof
GB0320590D0 (en) Fixing means and methods
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
GB0228525D0 (en) Polymers and their use
IL165932A0 (en) Osteopontin oligodendrocytes and myelination
GB0224017D0 (en) Osteopontin oligodendrocytes and myelination
EP1487547A4 (en) Physical interaction means and related uses thereof
AU2003228397A8 (en) Hausp-p53 interaction and uses thereof
GB0207624D0 (en) Chemokine and uses thereof
AU2003216442A8 (en) Enkurin and uses thereof
GB0203528D0 (en) Process and composition
AU2003223357A8 (en) Compounds and methods
GB0216530D0 (en) Methods and means
GB0216529D0 (en) Methods and means
GB0216755D0 (en) Methods and means
GB0207414D0 (en) Methods and means